User profiles for "author:Lisa Butterfield"

Lisa H. Butterfield

University of California San Francisco
Verified email at ucsf.edu
Cited by 19735

Immunotherapy of cancer in 2012

JM Kirkwood, LH Butterfield, AA Tarhini… - CA: a cancer journal …, 2012 - Wiley Online Library
The immunotherapy of cancer has made significant strides in the past few years due to
improved understanding of the underlying principles of tumor biology and immunology …

[PDF][PDF] Current developments in cancer vaccines and cellular immunotherapy

A Ribas, LH Butterfield, JA Glaspy… - Journal of clinical …, 2003 - Citeseer
This article reviews the immunologic basis of clinical trials that test means of tumor antigen
recognition and immune activation, with the goal to provide the clinician with a mechanistic …

Dendritic cell–based cancer vaccines

PM Santos, LH Butterfield - The Journal of Immunology, 2018 - journals.aai.org
Dendritic cells (DC) are specialized immune cells that play a critical role in promoting an
immune response against Ags, which can include foreign pathogenic Ags and self-tumor …

B cells and tertiary lymphoid structures promote immunotherapy response

BA Helmink, SM Reddy, J Gao, S Zhang, R Basar… - Nature, 2020 - nature.com
Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer
therapy. Until now, predictive biomarkers,,,,,,,,–and strategies to augment clinical response …

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

HA Tawbi, M Burgess, V Bolejack, BA Van Tine… - The Lancet …, 2017 - thelancet.com
Background Patients with advanced sarcomas have a poor prognosis and few treatment
options that improve overall survival. Chemotherapy and targeted therapies offer short-lived …

[HTML][HTML] Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 …

LJ Padrón, DM Maurer, MH O'Hara, EM O'Reilly… - Nature medicine, 2022 - nature.com
Chemotherapy combined with immunotherapy has improved the treatment of certain solid
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma …

[HTML][HTML] Induction of CD8+ T-cell responses against novel glioma–associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic …

H Okada, P Kalinski, R Ueda, A Hoji… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
Purpose A phase I/II trial was performed to evaluate the safety and immunogenicity of a
novel vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic …

A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides

LH Butterfield, A Ribas, VB Dissette, Y Lee… - Clinical Cancer …, 2006 - AACR
Abstract α-Fetoprotein (AFP) is a self protein expressed by fetal liver at high levels, but is
transcriptionally repressed at birth. AFP is up-regulated in hepatocellular carcinomas, and …

T-cell responses to HLA-A* 0201 immunodominant peptides derived from α-fetoprotein in patients with hepatocellular cancer

LH Butterfield, A Ribas, WS Meng, VB Dissette… - Clinical Cancer …, 2003 - AACR
Purpose: An existing immunological paradigm is that high concentrations of soluble protein
contribute to the maintenance of peripheral tolerance/ignorance to self protein. We tested …

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

FS Hodi, S Lee, DF McDermott, UN Rao, LH Butterfield… - Jama, 2014 - jamanetwork.com
Importance Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) blockade with
ipilimumab prolongs survival in patients with metastatic melanoma. CTLA-4 blockade and …